fda glp-1 warning news november 2025 Covering Drugs: Employers' Top Questions Answered – Sequoia The growing availability of compounded

Sustained weight loss could make dual GLP-1/GIP receptor agonists more attractive to payers, and increase the affordability of these drugs for healthcare systems

In clinical practice, GLP-1 receptor agonists are used to manage type 2 diabetes and increasingly for weight-loss or metabolic indications

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled trial

Health economics and outcomes research (HEOR): Evaluate cost-effectiveness, resource utilization, and outcomes compared to other interventions like bariatric surgery